Treatment patterns and outcomes of patients hospitalized for leptospirosis in endemic and non-endemic regions in Japan, 2010-2023: A nationwide inpatient database study.
{"title":"Treatment patterns and outcomes of patients hospitalized for leptospirosis in endemic and non-endemic regions in Japan, 2010-2023: A nationwide inpatient database study.","authors":"Satoshi Miike, Yuichiro Matsuo, Yusuke Sasabuchi, Shotaro Aso, Kiyohide Fushimi, Hiroki Matsui, Hideo Yasunaga","doi":"10.1016/j.jiac.2025.102786","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Leptospirosis is endemic to Okinawa but non-endemic to other regions (non-Okinawa) of Japan. We evaluated the characteristics, treatment, and outcomes of patients with leptospirosis in and outside Okinawa.</p><p><strong>Methods: </strong>Using a Japanese national inpatient database, we identified patients hospitalized with leptospirosis between 2010 and 2023. Data on patient characteristics, antibiotic treatment, need for intensive care, and outcomes were collated and compared between patients in and outside Okinawa.</p><p><strong>Results: </strong>Among 342 patients, 162 were hospitalized in Okinawa, whereas 180 outside Okinawa. Okinawan patients were younger than non-Okinawan patients (median age: 35.5 vs. 54 years). Over 80 % received beta-lactams. Broad-spectrum beta-lactams or combination therapy with tetracyclines were administered more commonly outside Okinawa. Patients outside Okinawa required intensive care more frequently. The overall mortality rate was 1.2 %.</p><p><strong>Conclusion: </strong>Antimicrobial prescription patterns and intensive care requirements varied between the two regions. These disparities may be attributed to variations in physicians' diagnostic thresholds or diagnostic delays outside Okinawa.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102786"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jiac.2025.102786","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Leptospirosis is endemic to Okinawa but non-endemic to other regions (non-Okinawa) of Japan. We evaluated the characteristics, treatment, and outcomes of patients with leptospirosis in and outside Okinawa.
Methods: Using a Japanese national inpatient database, we identified patients hospitalized with leptospirosis between 2010 and 2023. Data on patient characteristics, antibiotic treatment, need for intensive care, and outcomes were collated and compared between patients in and outside Okinawa.
Results: Among 342 patients, 162 were hospitalized in Okinawa, whereas 180 outside Okinawa. Okinawan patients were younger than non-Okinawan patients (median age: 35.5 vs. 54 years). Over 80 % received beta-lactams. Broad-spectrum beta-lactams or combination therapy with tetracyclines were administered more commonly outside Okinawa. Patients outside Okinawa required intensive care more frequently. The overall mortality rate was 1.2 %.
Conclusion: Antimicrobial prescription patterns and intensive care requirements varied between the two regions. These disparities may be attributed to variations in physicians' diagnostic thresholds or diagnostic delays outside Okinawa.
期刊介绍:
The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.